RMD

The Week

Resmed (RMD) fell 4.41% this week to close at $218.27, underperforming the S&P 500 by about 3.61 percentage points. The four-day trading week had a choppy downward tilt. On Tuesday (Sep 8), the stock opened at $226.22 and slid to $221.05, a 3.15% drop. Losses narrowed over the next two sessions, with Thursday (Sep 10) touching an intraday low of $215.80. Friday (Sep 11) saw limited movement, ending at $218.27 with a weekly amplitude of 4.8%.

Key Events

A few company-related developments marked the week. Early on, ResMed adjusted CDI and share counts in connection with cross-market transfers and buybacks. On the institutional side, the Saudi Central Bank and the California State Teachers Retirement System were mentioned in weekly filings or reports as adding positions, suggesting some long-horizon capital remained active. On Thursday (Sep 10), CEO Michael J. Farrell disposed of common shares worth $1,110,188.53. Meanwhile, an industry item noted the high flow nasal cannula market is projected to reach $1.44 billion by 2031, a segment relevant to ResMed’s respiratory care business.

Analyst Ratings

As of this week, 20 brokers cover Resmed: 6 rate it buy, 1 rates it over, 11 rate it hold, 1 rates it under and 1 rates it sell, with 1 having no opinion. The consensus rating is buy, with an average target of $246.4375, about 12.9% above the latest close of $218.27. Targets span a wide range from $175 to $320, pointing to meaningful dispersion across brokers. Within the medical devices industry, Resmed ranks 11th out of 142 names on rating strength.

The Week Ahead

Next week is heavy on macro data. The New York Fed manufacturing index is due on Tuesday (Sep 15), with a prior reading of 20.6 and a forecast of 14.75. Wednesday (Sep 16) brings retail sales excluding autos, import prices, retail sales and the NAHB housing market index; retail sales previously came in at -0.6 and is expected to print 0.9. These releases will shape the market’s view on consumer and manufacturing momentum.

In Short

The week delivered a pullback for Resmed, yet the street still holds a buy consensus with a target roughly 12.9% above spot, leaving a gap between near-term price action and longer-term broker views. In the latest session, institutional money was a net buyer while small-lot flows leaned net seller. The next test is how next week’s macro data feeds into sentiment for consumer and medical-device names.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.